Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2011-08-02
2011-08-02
Fetterolf, Brandon (Department: 1628)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S247000, C514S252160, C540S594000, C544S278000
Reexamination Certificate
active
07989445
ABSTRACT:
The present invention relates to a compound represented by the formula:whereinAr is an optionally substituted ring;A is a spacer having a main chain of 1 to 4 atoms;B is a bond, a C1-10alkylene group or an oxygen atom;R3and R5are each independently a hydrogen atom or a substituent;R4is an optionally substituted cyclic group or an optionally substituted C1-10alkyl group; andR1and R2are each independently a hydrogen atom or a substituent, orR1and R2or R1and B are bonded to form an optionally substituted nitrogen-containing heterocycle, orR1and Ar are bonded to form an optionally substituted nitrogen-containing fused heterocycle, or a salt thereof. The thienopyrimidone compound of the present invention has a superior melanin-concentrating hormone receptor antagonistic action, and is useful as an agent for the prophylaxis or treatment of obesity and the like.
REFERENCES:
patent: 2003/0158177 (2003-08-01), Ishihara et al.
patent: 2004/0077628 (2004-04-01), Ishihara et al.
patent: 2004/0220404 (2004-11-01), Carpenter et al.
patent: 2005/0209213 (2005-09-01), Ishihara et al.
patent: 2006/0128690 (2006-06-01), Ishihara et al.
patent: 1283199 (2003-02-01), None
patent: 1285651 (2003-02-01), None
patent: 1447402 (2004-08-01), None
patent: WO 01/21577 (2001-03-01), None
patent: WO 03/033476 (2003-04-01), None
patent: WO 2004/092181 (2004-10-01), None
Stella, Valentino. J. Expert Opinion of Therapeutic Patents, Prodrugs as therapeutics, 2004, 14(3): 277-280.
Testa, Bernard. Biochemical Pharmacology, Prodrug Research: futile or fertile?. 68(2004): 2097-2106.
Ettmayer, Peter. Medicinal Chemistry, Lessons Learned from Marketed and Investigational Prodrugs, 47(10), 2004: 2394-2404.
Schaefer et al. Failure is not an option: learning from unsucessful proof-of-concept trials. Drug Discovery Today, 2008, 13: (21/22), 913-916.
Horig et al. Review: from bench to clinic and back: Perspective on the 1stIQPC Translational Research Conference. Journal of Translational Medicine, 2004, 2(44).
J.G. Cannon. Chapter Nineteen in Burger's Medicinal Chemistry and Drug Discovery, Fifth Edition, vol. I: Principles and Practice, Wiley-Interscience, 1995, pp. 783-802.
Meyer et al. Structure-activity studies for a novel series of bicyclic substituted hexahydrobenz[e]isoindole alpha1A adrenoceptor antagonist as potential agents for the symptomatic treatment of benign prostatic hyperplasia. J. Med. Chem. 2001, 44, 1971-1985.
Friedman et al. Leptin and the regulation of body weight in mammals. Nature. vol. 395, 1996.
Search Report for Corresponding European Application No. 06746033.7 dated Aug. 11, 2009.
Makino Shingo
Murata Toshiki
Conlin David G.
Edwards Angell Palmer & & Dodge LLP
Fetterolf Brandon
Kim Dwight D.
Pagonakis Anna
LandOfFree
Thienopyrimidone compound does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Thienopyrimidone compound, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Thienopyrimidone compound will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2626051